Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations

NCT07670156 is registered in ClinicalTrials.gov with Lisa Satter as lead sponsor.

NCT NCT07670156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07670156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations
Lead sponsor
Lisa Satter
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
August 31, 2028
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

jak1 gof, stat1 gof, stat3 gof, stat5b gof, stat6 gof